Equity Research, Broker Reports, and media content on AstraZeneca

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about AstraZeneca
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on AstraZeneca. We currently have 126 research reports from 10 professional analysts.

Open
7739p
Range Today
7692/7948p
52 Week
5325/7948p
Daily Volume
1.9m
# Shares
1,312m
Daily Liquidity
(0.14%)
Pension Liability
£2,842m
Enterprise Value
£110,417m
Market Cap
£103,370m
Latest PE (hist)
16.66
Div Yield
3.82
Date Source Announcement
13Jan20 07:01 RNS Lynparza granted FDA Priority Review for PAOLA-1
13Jan20 07:00 RNS Update on Epanova Phase III STRENGTH trial
06Jan20 07:01 RNS Farxiga granted FDA heart failure Priority Review
06Jan20 07:00 RNS Lokelma approved in China for hyperkalaemia
02Jan20 15:00 RNS Total Voting Rights
30Dec19 07:00 RNS US FDA approved Lynparza for pancreatic cancer
23Dec19 07:00 RNS Triple-combination approved in China for COPD
  • Frequency of research reports

     

  • Research reports on

    AstraZeneca

  • Providers covering

    AstraZeneca